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Review Article
Urinary Tract Infection in Postmenopausal Women
Raul Raz
Infectious Diseases Unit, Ha'Emek Medical Center, Afula, Rappaport Faculty of Medicine, Technion, Haifa, Israel
Urinary tract infection (UTI) is the most common bacterial infection in women in gen-
eral and in postmenopausal women in particular. Two groups of elderly women with 
recurrent UTI should be differentiated regarding age and general status: healthy, 
young postmenopausal women aged 50 to 70 years who are neither institutionalized 
or catheterized and elderly institutionalized women with or without a catheter. 
Bacteriuria occurs more often in elderly functionally impaired women, but in general 
it is asymptomatic. However, the risk factors associated with recurrent UTI in elderly 
women are not widely described. In a multivariate analysis it was found that urinary 
incontinence, a history of UTI before menopause, and nonsecretor status were strongly 
associated with recurrent UTI in young postmenopausal women. Another study de-
scribed the incidence and risk factors of acute cystitis among nondiabetic and diabetic 
postmenopausal women. Independent predictors of infection included insulin-treated 
patients and a lifetime history of urinary infection. Borderline associations included 
a history of vaginal estrogen cream use in the past month, kidney stones, and asympto-
matic bacteriuria at baseline. Another important factor in postmenopausal women is 
the potential role that estrogen deficiency plays in the development of bacteriuria. 
There are at least two studies showing a beneficial effect of estrogen in the management 
of recurrent bacteriuria in elderly women. One of these studies showed that vaginal 
estrogen cream reduced vaginal pH from 5.5±0.7 to 3.6±1.0, restored lactobacillus, and 
decreased new episodes of UTI. Another study reported similar results using an estriol 
vaginal ring. However, contradictory results are found in the literature. For example, 
additional studies found that the use of estriol-containing vaginal pessaries was less 
effective than oral nitrofurantoin macrocrystals in preventing UTI in postmenopausal 
women. Two other studies also did not find any benefit in the reduction of UTI by oral 
estrogen therapy. Unfortunately, the use of estrogen in preventing UTI in post-
menopausal women remains questionable. New strategies have been researched for 
reducing the use of antibiotics in the prevention and treatment of UTI. Two of them 
are probiotics and cranberry juice or capsules. Although several studies regarding pro-
biotics and cranberry juice or capsules have reported a reduction of episodes of UTI, 
there is no conclusive evidence that they are useful in the prevention of UTI in post-
menopausal women. As for the optimal drug, dosage, and length of treatment for UTI 
in the elderly, there are no studies comparing these data with the treatment for young 
women.
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INTRODUCTION
Urinary tract infection (UTI) is the most common bacterial 
infection in young and elderly women. Despite the higher 
incidence of bacteriuria in elderly women, most UTI re-
search has been conducted in young women. This chapter 
will discuss epidemiological studies regarding risk factors 
associated with bacteriuria in elderly women. Bacteriuria 
in the elderly is associated with high mortality rates; how-
ever, in most cases, bacteriuria is asymptomatic and not 
a causal factor of death. 
Estrogen deficiency plays an important role in the devel-
opment of bacteriuria. Several studies have been con-
ducted showing the efficacy of estrogen (orally and vagi-
nally) in the prevention of UTI. Yet, the literature is divided 
on this subject, and other studies have not shown any ad-
vantage in using estrogen. 
This chapter will focus on the updated known data re-
garding the use of estrogen in the prevention of bacteriuria 
in elderly women. The alarming increase in multi-
drug-resistant uropathogens makes it imperative that al-
ternative strategies are found. One strategy is the restora-
tion of flora with lactobacilli using probiotics and another 
is the use of cranberry, a competitive compound that in-
hibits the attachment of bacteria to the uroepithelial muco-
sa and thereby reduces the frequency of UTI. 
METHODOLOGY
A systematic literature search was performed of studies 
conducted over the past 15 years. A few recent studies have 
investigated the management of UTI in postmenopausal 
women. The data were collected from the most up-to-date 
published studies and guidelines, which were found by 
searching Medline, PubMed, and the Cochrane database 
with the following key words: ‘bacteriuria in elderly wom-
en’ and ‘postmenopausal women and UTI’. A total of 190 
papers were screened by title and abstract: 111 for the first 
keyword and 79 for the second. Only English publications 
addressing the keywords were screened.
The 25 references used in the text were assessed accord-
ing to the level of scientific evidence involved. The studies 
were rated according to the level of evidence (LoE) and the 
grade of recommendations (GoR) by using ICUD standards 
[1,2].
DEMOGRAPHY
UTI is the most common bacterial infection in women. 
Three groups of women with recurrent UTI should be dis-
tinguished on the basis of age: premenopausal women, 
healthy postmenopausal women between the ages of 50 to 
70 years who are neither institutionalized nor cathe-
terized, and elderly institutionalized women, who are in 
many cases catheterized. 
Bacteriuria occurs more often in functionally impaired 
women than in those who are not impaired; persistent bac-
teriuria is seen more often in nursing home residents, and 
transient bacteriuria is seen more often in young, healthy 
postmenopausal women. The majority of elderly women 
with bacteriuria are asymptomatic and should not be treat-
ed with antibiotics (LoE 1b) [3,4]. In young to middle-aged 
women, the prevalence of UTI is ＜5%, rising considerably 
with advancing age. Epidemiologic studies have shown 
that 15% to 20% of 65-70 year-old women have bacteriuria, 
compared with 20% to 50% of women ＞80 years old.
Despite the high incidence of bacteriuria in post-
menopausal women (young and institutionalized), most 
UTI research has been conducted in younger women. 
Hence, the most common UTI risk factors among healthy 
younger women, such as frequent vaginal intercourse, 
spermicide use, diaphragm use, condom use, a previous 
UTI history, recent antibiotic use, and nonsecretor status, 
were not widely investigated in middle-aged and elderly 
women (LoE 2a) [5].
BACTERIURIA IN YOUNG VS. ELDERLY WOMEN
Foxman et al conducted a case-control study investigating 
the role of health behavior and sexual and medical history 
in UTI risk among otherwise healthy women aged 40 to 65 
years [4]. They showed that sexual activity was not asso-
ciated with acquiring UTI in this age group, whereas a his-
tory of UTI during the past year, urine loss, antibiotic use 
during the previous 2 weeks, and exposure to cold during 
the previous 2 weeks were positively associated with UTI. 
In addition, drinking cranberry juice and taking vitamin 
C were moderately protective (LoE 2b) [4]. 
RISK FACTORS
A case-control study compared 149 postmenopausal wom-
en with a history of recurrent UTI with 53 age-matched 
women with no history of UTI. They looked for risk factors 
in healthy noninstitutionalized and noncatheterized 
women. Three urological factors, namely, incontinence 
(41% of case patients vs. 9% control patients; p＜0.001), 
presence of a cystocele (19% vs. 0%; p＜  0.001), and post-
voiding residual volume (28% vs. 2%; p＜0.000008) were 
strongly associated with recurrent UTI. Multivariate anal-
ysis showed that urinary incontinence (odds ratio [OR], 
5.79; 95% confidence interval [CI], 2.05-16.42; p=0.0009), 
a history of UTI before menopause (OR, 4.85; 95% CI, 
1.7-13.84; p＜0.003), and nonsecretor status (OR, 2.9; 95% 
CI, 1.28-6.25; p=0.005) were most strongly associated with 
recurrent UTI in postmenopausal women (LoE 2a) [5].
Jackson et al described the incidence and risk factors for 
acute cystitis among nondiabetic and diabetic post-
menopausal women and the possible effect of estrogens on 
those women (LoE 2a) [6]. During 1,773 person-years of fol-
low-up, 138 symptomatic UTIs occurred (incidence, 0.07 
person-year). Independent prediction of infection included 
insulin-dependent diabetes mellitus (hazard ratio 95% CI, 
1.7-7.0) and a lifetime history of UTI (hazard ratio for six Korean J Urol 2011;52:801-808
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TABLE 1. Major factors predisposing adult women to UTI as 
related to age [9]
Age group (yr) Predisposing factor
15-50
50-70
＞70 
Sexual intercourse, Diaphragm/spermicide, 
Spermicide, Antimicrobials, Prior UTI, 
Maternal history of UTI, Childhood history 
of UTI, Nonsecretor status
Lack of estrogen, Urogenital surgery, 
Incontinence, Cystocele, Postvoid residual 
urine, Nonsecretor status, Prior UTI
Catheterization, Incontinence, Urogenital 
surgery
UTI: urinary tract infection
FIG. 1. Relationship between estrogen and the vaginal flora and 
pathophysiology of urinary tract infections in elderly women 
[17].
or more infections, 6.9; 95% CI, 3.5-13.6). However, a bor-
derline association included a history of vaginal estrogen 
cream use in recent months (hazard ratio, 1.8; 95% CI, 
1.0-3.4), and a history of kidney stones (hazard ratio, 1.95; 
95% CI, 0.9-3.5). However, sexual activity, urinary incon-
tinence, parity, postcoital urination, vaginal dryness, use 
of cranberry juice, vaginal bacterial flora, and postvoid re-
sidual bladder volume were not associated with the in-
cidence of acute cystitis after multivariable adjustment. 
A study by Moore et al found that recent sexual inter-
course, as described for younger women, was also strongly 
associated with incident UTI in other healthy postmeno-
pausal women (LoE 2b) [7]. In the older, institutionalized 
women, urine catheterization and functional status deteri-
oration appeared to be the most important risk factors asso-
ciated with UTI (LoE 2a) [8]. The risk of UTI increases dra-
matically with catheterization. Table 1 describes the major 
factors predisposing adult women to UTI as related to age 
[9].
BACTERIURIA AND MORTALITY
Bacteriuria has been discovered as a cause of increased 
mortality in elderly individuals. Studies of Greek, Finnish, 
and American patients showed decreased longevity asso-
ciated with UTI (LoE 1b) [10-12]. The elderly patients with 
UTI were suffering from a variety of diseases other than 
UTI that might have increased their susceptibility to in-
fections as well as their mortality. 
Nordestam et al studied a population of elderly patients 
and compared their longevity in relation to bacteriuria 
(LoE 1b) [13]. There was no increase in mortality related 
to bacteriuria for otherwise healthy individuals. Bacteriu-
ria per se did not appear to be a risk factor for mortality. 
In patients with concomitant disease, bacteriuria was as-
sociated with increased mortality, but it is not the cause. 
THE ROLE OF ESTROGEN
Another important factor in postmenopausal women is the 
potential role that estrogen deficiency plays in the develop-
ment of bacteriuria. Postmenopausal women frequently 
present with genitourinary symptoms; half have genito-
urinary disorders, and 29% have urinary incontinence 
(LoE 1b) [14]. Postmenopause is characterized by a sig-
nificant reduction in ovary estrogen secretion, which is of-
ten associated with vaginal atrophy. Clinically, it mani-
fests as a syndrome characterized by vaginal dryness, itch-
ing, dyspareunia, and urinary incontinence. This may 
sometimes imitate a UTI (LoE 2a) [15,16]. 
Estrogen stimulates the proliferation of lactobacillus in 
the vaginal epithelium, reduces pH, and avoids vaginal col-
onization of Enterobacteriaceae, which are the main 
pathogens of the urinary tract. Fig. 1 describes the relation-
ship between estrogen and the vaginal flora and the patho-
physiology of urinary tract infections in elderly women 
(LoE 1a) [17]. In addition, the absence of estrogen decreases 
the volume of the vaginal muscles, resulting in slackness 
of the ligaments holding the uteric pelvic floor and the blad-
der, resulting in the development of prolapse of the internal 
genitalia. Kicovic et al showed that vaginal cream de-
creased urogenital complaints associated with atrophic 
vaginitis (LoE 1b) [18]. 
A previous randomized, double-blind, placebo-con-
trolled study demonstrated that vaginal estriol treatment 
had a dramatic effect on recurrent UTIs in postmenopausal 
women. The results showed that the incidence of UTI in 
women who received vaginal estriol was reduced to 0.5 epi-
sodes per year compared with 5.9 episodes per year in wom-
en who received placebo. In addition, after 1 month of treat-
ment, lactobacillus appeared in 60% of the estro-
gen-treated group but in none of the placebo group, and the 
vaginal pH decreased from 5.5±0.7 before treatment to 
3.6±1.0 after treatment (LoE 1a) [19]. 
Several years later, similar results were obtained by 
Eriksen, using an estradiol-vaginal ring (LoE 1b) [20]. In 
that study, the women in the estradiol group had a sig-
nificant reduction in the frequency of urogenital symp-
toms, such as vaginal dryness, dyspareunia, and urge and 
stress incontinence after 36 weeks of study. In addition, 
45% of the women receiving estradiol were still free of UTI, 
in contrast with only 20% of the women treated with 
placebo.Korean J Urol 2011;52:801-808
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TABLE 2. Indications and contraindications for estrogen therapy 
in UTI [3]
Indications
Oral therapy
    - Young postmenopausal 
women
Vaginal therapy
    - Women ＞60 years old
Advantages
    - Avoid menopausal 
symptoms
    - Prevent osteoporosis
    - Prevent ischemic heart 
disease
    - Prevent UTI
Advantages
    - Improve symptoms related 
to atrophic vaginitis
    - Improve urge incontinence
    - Prevent UTI
Contraindications
Absolute
- Endometrial carcinoma
- Breast carcinoma
- Thromboembolic disorders
- Liver disease
Relative
- High blood pressure?
- Diabetes mellitus?
- Gallstones?
Difficulties in vaginal therapy
Physical limitations
Tremor, obesity, status after cerebrovascular accident, dementia, 
psychological problems, education/cultural behavior
However, contradicting results are found in the 
literature. For example, another study showed that the use 
of estriol-containing vaginal pessaries was less effective 
than the use of oral nitrofurantoin macrocrystals in the 
prevention of bacteriuria in postmenopausal women. This 
study also showed the failure of the estriol-containing vagi-
nal pessaries to restore vaginal lactobacilli and to reduce 
vaginal pH in those women (LoE 1a) [21].
Brown et al assessed the effects of hormonal therapy on 
UTI frequency and examined potential risk factors (LoE 3) 
[22]. They used data from the Health and Estrogen/Proges-
terone Replacement Study, a randomized, blinded trial of 
the effect of hormone therapy on coronary heart disease 
events among 2,763 postmenopausal women aged 44 to 79 
years with coronary diseases. UTI frequency was higher in 
the group receiving hormone treatment (0.625 mg con-
jugated estrogen plus 2.5 mg medroxyprogesterone acetate 
or placebo followed for a mean of 4.1 years), although the 
difference was not statistically significant. Statistically 
significant risk factors for UTI in the multivariate analysis 
included the following: women with diabetes mellitus in 
treatment (insulin OR, 1.81; 95% CI, 1.4-2.34), oral medi-
cation (OR, 1.44; 95% CI, 1.09-1.9), poor health (OR, 1.34; 
95% CI, 1.14-1.57), vaginal itching (OR, 1.63; 95% CI, 
1.07-2.5), and urge incontinence (OR, 1.51; 95% CI, 
1.30-1.75). UTIs in the previous years were strongly asso-
ciated with a simple UTI (OR, 7.00; 95% CI, 5.91-8.92) as 
well as with multiple UTIs (OR, 18.51; 95% CI, 
14.27-24.02). 
Jackson et al did not see that the use of oral or vaginal 
estrogen was a protective factor in order to avoid recurrent 
UTI (LoE 2a) [6].
In conclusion, the efficacy of estrogen in the prevention 
of UTI in postmenopausal women with recurrent infections 
remains questionable. From a clinical perspective, the 
main currently recommended use of estrogen (probably 
vaginal and not oral) is in postmenopausal women, espe-
cially those infected with multidrug-resistant uropath-
ogens, which limits the options and effectiveness of anti-
microbial prophylaxis, and in women in whom the symp-
toms are related to atrophic vaginitis (5). Table 2 summa-
rizes the indications and contraindications for estrogen 
therapy in UTI [3].
TREATMENT
Treatment of acute cystitis and pyelonephritis in other-
wise healthy postmenopausal women is similar to that in 
premenopausal women; however, short- term therapy in 
postmenopausal women is not as well documented by con-
trolled studies as in younger women. Raz and Rozenfeld 
published a study in postmenopausal women (mean age 65 
years) with uncomplicated UTI in which ofloxacin, 200 mg 
once daily for 3 days (LoE 1b) [23], was significantly more 
effective in both short- and long-term follow-up than a 7 day 
course of cephalexin, 500 mg four times daily, even though 
all the uropathogens were susceptible to the two agents. In 
another double-blind study (LoE 1b), including a total of 
183 postmenopausal women of at least 65 years of age with 
acute uncomplicated UTI, similar results were obtained 
with either a 3-day or a 7-day oral course of ciprofloxacin 
250 mg two times daily (bacterial eradication 2 days after 
treatment 98% vs 93%, p=0.16), but the shorter course was 
better tolerated. The rate of bacterial eradication in this 
study was generally high, and the rate of bacterial resist-
ance to ciprofloxacin low (GoR A) [24].
Asymptomatic bacteriuria in elderly women should not 
be treated with antibiotics (GoR A).
The optimal antimicrobials, dosages, and duration of 
treatment in elderly women appeared to be similar to those 
recommended for young postmenopausal women (GoR C). 
However, these results should not be extended to the frail 
elderly geriatric population with significant comorbidities, 
who frequently present with UTI caused by more resistant 
Gram-negative organisms and in whom treatment dura-
tion should be prolonged as in complicated UTI. 
Estrogen (especially vaginal) could be administered for 
prevention of UTI; yet, the results are conflicting (GoR C). 
There are at least two clinical studies showing that vaginal 
estriol and estradiol-releasing vaginal rings restore vagi-
nal flora, reduce pH, and reduce the number of sympto-
matic bacteriuria [19,20]. However, it appears that oral es-
trogen does not reduce the incidence of UTI in post-
menopausal women (Hooton et al). 
Alternative methods, like cranberry and probiotic lacto-Korean J Urol 2011;52:801-808
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bacilli, can contribute to preventing recurrent UTI in post-
menopausal women, but more well-conducted studies are 
required to define their exact role and efficiency (GoR C). 
Once complicating factors, such as urinary obstruction, 
neurogenic bladder disturbances, etc, can be ruled out, an 
antimicrobial prophylaxis should be carried out as recom-
mended for premenopausal women (GoR C).
NEW STRATEGIES
The alarming increase in multidrug-resistant uropath-
ogens makes it imperative that alternative strategies are 
found. One strategy is the restoration of the normal flora 
with lactobacilli using probiotics. Another option is the use 
of a competitive compound that inhibits attachment of bac-
teria to the uroepithelium. Unfortunately, both methods 
have been evaluated without conclusive results, although 
there is some evidence that probiotics and cranberry are 
useful in preventing UTI.
Reid et al demonstrated the possibility of preventing ur-
opathogen infection by using lactobacillus in vitro [25]. 
Several clinical studies showed that L. rhamnosus Gr-1 
and L. fermentum-RC can colonize the vagina, a first step 
in preventing bacteriuria (LoE 2a). However, more studies, 
especially clinical studies, should be carried out to de-
termine the role of probiotics in the prevention of UTI. 
Another possibility is the use of cranberry. Cranberries 
contain a proanthocyanidin that can prevent the colo-
nization of the E. coli uropathogen in the vaginal mucosa 
and reduce the frequency of bacteriuria (GoR C) [26]. 
McMurdo et al carried out a randomized controlled trial in 
elderly women to compare the efficacy in preventing UTI 
of cranberry capsules with trimethoprim (GoR C) [27]. The 
time to first recurrence of UTI was not significantly differ-
ent between groups. In addition, trimethoprim had a very 
limited advantage over cranberry in the prevention of re-
current UTI in older women but had more adverse effects 
and withdrawals. 
However, few clinical studies have been conducted, al-
though in small and heterogenic populations, an advant-
age in the use of cranberry juice or other oral preparations 
in the prevention of bacteriuria has been shown. In the eld-
erly population, there is only one clinical quasi-random-
ized study in elderly women with asymptomatic bacter-
iuria, which showed that bacteriuria and pyuria were sig-
nificantly reduced in women taking cranberry juice in com-
parison with women who received placebo (GoR C) [28]. 
Because asymptomatic bacteriuria in the elderly is not 
treated, however, the clinical significance of this study re-
mains inconclusive. 
FURTHER RESEARCH
Further wide-scale randomized studies are essential to de-
fine and establish the exact role of estrogen therapy, pro-
biotics, lactobacilli, and other possible and available meth-
ods to reduce the use of antibiotics. 
CONCLUSIONS
Bacteriuria, particularly asymptomatic bacteriuria, is a 
very frequent finding in both healthy postmenopausal and 
institutionalized women. Urological factors, such as uri-
nary incontinence, presence of any grade of cystocele and 
postvoiding residual volume, together with previous UTI 
and nonsecretor status, are associated with recurrent UTI 
in this population. Some studies showed a relationship be-
tween bacteriuria with diabetes or sexual intercourse. The 
role of vaginal or oral estrogen together with the use of pro-
biotics and lactobacilli remains questionable. 
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TABLE 1. Host risk factors in urinary tract infections categorized according to the ORENUC system
Phenotype Category of risk factor Examples of risk factors
O
R
E
N
U
C
NO known risk factor
Risk factors for Recurrent UTI, but no risk of more severe outcome
Extra-urogenital risk factors with risk of more severe outcome
Nephropathic diseases with risk of more severe outcome
Urological risk factors with risk of more severe outcome, which can 
be resolved during therapy
Permanent urinary Catheter and nonresolvable urological risk 
factors with risk of more severe outcome
Otherwise healthy premenopausal women
Sexual behaviour (frequency, spermicide)
Hormonal deficiency in postmenopause
Secretor type of certain blood groups
Well-controlled diabetes mellitus
Prematurity, newborn
Pregnancy
Male gender
Badly controlled diabetes mellitus
Relevant immunosuppression (not well defined)
Relevant renal insufficiency (not well defined)
Polycystic nephropathy
Interstitial nephritis, e.g., due to analgetics
Ureteral obstruction due to a ureteral stone 
Well-controlled neurogenic bladder disturbances
Transient short-term external urinary catheter
Asymptomatic bacteriuria
a
Long-term external urinary catheter
Nonresolvable urinary obstruction
Badly controlled neurogenic bladder disturbances
a: Only under certain circumstances in combination with other risk factors, e.g., pregnancy, urological intervention. From Truls et al 
[3]
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Urinary tract infection (UTI) is the most common bacterial 
infection in women in general and in postmenopausal wom-
en in particular. Whereas UTI in otherwise healthy women 
is considered as ‘uncomplicated’ UTI, in some guidelines, 
UTI in postmenopausal women is considered as ‘complicat-
ed’ UTI. Such a generalization may not be justified, how-
ever, because the different situation of the host in this pop-
ulation has to be considered more carefully. In his article 
on UTI in postmenopausal women, Raul Raz substratifies 
the population into at least two groups regarding age and 
general status: 1) (otherwise) healthy, young postmeno-
pausal women aged about 50 to 70 years who are neither 
institutionalized nor catheterized, and 2) elderly (functio-
nally impaired) institutionalized women with or without 
a urinary catheter. Concerning impact and outcome, UTI 
in the first group is much more closely related to ‘uncompli-
cated’ UTI in otherwise healthy premenopausal women 
than to the ‘complicated’ UTI found in patients with under-
lying urological anomalies. In the Antimicrobial Resis-
tance Epidemiology in Females with Cystitis (ARESC) 
study [1], the proportion of Escherichia coli in sympto-
matic, uncomplicated cystitis of 1,261 premenopausal, 
nonpregnant women without diabetes mellitus and with-
out recurrent UTI (two or more within 6 months or three 
or more within 1 year) was 80.8% and not significantly dif-
ferent from the proportion (80.3%) in 762 (otherwise 
healthy) postmenopausal women without diabetes melli-
tus and without recurrent UTI up to an age of 65 years. Korean J Urol 2011;52:801-808
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Therefore, UTI in this group of postmenopausal women 
was considered ‘uncomplicated’ in the recently published 
German guideline on uncomplicated UTI [2]. UTI in the 
second group as described by Raul Raz has to be considered 
at least as ‘health care associated’ and most often also as 
‘complicated’ if the patient is catheterized or if other com-
plicating factors are present. It is also important to consid-
er the risk factors for recurrent UTIs, which are also com-
mon in postmenopausal women. For the first group aged 
between 50 and 70 years, these are mainly lack of estrogen, 
urogenital surgery, incontinence, cystocele, postvoid re-
sidual urine, prior UTI, and nonsecretor status. For the sec-
ond group aged over 70 years, these are mainly catheter-
ization, incontinence, urogenital surgery, diminished 
mental status, and former antimicrobial treatment. Also 
important is to note that there was no increase in mortality 
related to bacteriuria for otherwise healthy individuals. 
Bacteriuria per se did not appear to be a risk factor for 
mortality. Therefore, asymptomatic bacteriuria in elderly 
women should not be treated with antibiotics according to 
Raul Raz’s recommendation. In general, treatment of acute 
cystitis and pyelonephritis in otherwise healthy post-
menopausal women is similar to that in premenopausal 
women. In general, the application of the new ORENUC 
classification of UTI as proposed by the EAU/ESIU does 
better to differentiate between postmenopausal status per 
se (in otherwise healthy women) as a risk factor (for exam-
ple, for recurrent UTI) and postmenopausal status com-
bined with other risk factors (e.g., nephropathies or uro-
pathies) (Table 1) than does the classic system in which UTI 
is only substratified into ‘complicated’ and ‘uncomplicat-
ed’ UTI [3]. For prevention of recurrent UTI, the alarming 
increase in multidrug-resistant uropathogens makes it im-
perative to consider and to evaluate alternative strategies 
as pointed out by Raul Raz in his article.
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